Visit our Social Pages:

Posts classified under: SOM

  Home TTREC- Translational Therapeutics & Regenerative Engineering Center  /  Affiliated Faculty  /  SOM
Kevin Motz

Kevin Motz

Dr. Motz is a junior faculty member in the department of Otolaryngology-Head and Neck surgery and is working to establish himself as a successful clinician scientist. He has successful received career development funding (K23) through the NIDCD to investigate pathologic signaling pathways in macrophages associated with pathologic wound healing and subsequent fibrosis in the larynx and trachea. His research is complimentary to the work being done in TTEC. Cumulatively, Dr. Motz’s research is geared at identifying and targeting novel signaling pathways that drive airway fibrosis with the end goal of engineering a drug eluting biomaterial that can be used treat chronic wounds in the larynx trachea. This focus aligns well with the cross-cutting themes of Precision Medicine and Disease Modeling.

Arvind Pathak

Arvind Pathak

Dr. Pathak directs the Laboratory for Image-based Systems Biology, which works at the interface of engineering, medicine, and design to develop new hardware, software and “wetware” tools for basic and translational applications in tissue engineering and cancer. For the past several years he has collaborated with Dr. Grayson to spearhead the new field of “image-informed biomanufacturing” for tissue engineering applications. These efforts have included the development of novel in vivo and ex vivo imaging tools to acquire data to “inform” the design and deployment of more efficacious biomaterials for eventual clinical translation. More recently, he is collaborating with Dr. Grayson and other investigators to harness imaging and sensing technologies in health and disease models for applications in the Digital Twin (DT) and Precision Medicine (PM) space. Dr. Pathak has a long track record of leveraging in vitro, ex vivo, and in vivo imaging techniques for clinical biomarker development for cancer and other diseases. This includes multiscale imaging technologies and time-resolved characterization of disease evolution in vivo, all of which are critical for establishing the feasibility of DTs in the preclinical space. Dr. Pathak and his team are also leveraging cutting-edge miniaturized microscopy methods to characterize neurovascular changes longitudinally in preclinical models of brain aging. These approaches represent the first time that changes in multiple physiological variables can be measured continuously in vivo, over the lifetime of the aging model. These nascent studies have the potential to revolutionize our understanding of aging and its effects on the brain and other tissues. Finally, Dr. Pathak and his team are leveraging imaging-based artificial intelligence (AI) approaches to generate predictive models of engraftment success and biomaterial efficacy in vivo. Collectively, the imaging and computational tools that Dr. Pathak and his team are developing are synergistic with all the “Pillars” and “Horizontals” proposed in TTEC’s strategic plan for “Adaptive Therapeutics”, which make him an excellent fit as an affiliate faculty member of our Center.

Amer Riazuddin

Amer Riazuddin

I received PhD from the Department of Biochemistry and Molecular Biology, Johns Hopkins University School of Public Health (2002). Afterward, I completed two postdoctoral fellowships: first, at the National Eye Institute, National Institutes of Health, and second, at the McKusick-Nathans Institute of Genetic Medicine, here at Hopkins. Trained as an ocular geneticist, I have been involved in identifying the genetic basis of multiple inherited ocular diseases and understanding the underlying pathomechanism over the past two decades. In recent years, I have expanded the scope of my research to pluripotent stem cell-based regenerative medicine. Currently, my laboratory is validating stem cell-derived corneal endothelial cells as an alternative to donor tissue for the treatment of corneal endothelial dysfunction. Additionally, my laboratory is working on two research initiatives. First, the development of a non-surgical treatment of cataracts by perturbing lens cell pathways, and second, stem cell-based regeneration of the glaucomatous tissue as a possible treatment of glaucoma.

Gabsang Lee

Gabsang Lee

Our group has been focusing on how we can utilize human induced pluripotent stem cells (iPSCs) to model neural and muscle diseases in a hope to develop new therapeutic strategies. My lab is one of the first teams who utilized human iPSCs for disease modelling and drug discovery/validation, and recently we developed new human iPSC-based cell therapies for degenerative diseases and aging.

1 2